Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | P4HB | P07237 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25720520 | 0.84 | FFAR1 (0.53) | SMN1; SMN2 | |
| SCHEMBL30784948 | 0.83 | GSK3B (0.56) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3813604 | 0.83 | GSK3B (0.56) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL15281239 | 0.83 | KMT2A (0.50) | TSHRCLK1 | |
| SCHEMBL27782372 | 0.81 | GSK3B (0.53) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL286133 | 0.80 | MLYCD (0.51) | GSK3BTSHRALDH1A1POLB | |
| SCHEMBL5604959 | 0.79 | SMPD1 (0.63) | — | |
| SCHEMBL307622 | 0.79 | CES2 (0.62) | KDM4ESMN1; SMN2TSHRCLK1 | |
| SCHEMBL16214051 | 0.78 | MEN1 (0.46) | SMN1; SMN2ALDH1A1CLK1 | |
| Hydrochloric Acid SCHEMBL11688435 | 0.78 | GSK3B (0.50) | GSK3BHSD17B10KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-10889576-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2020-07-02 | — | — | US | disclosed |
| US-20190256505-A1 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10280160-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| EP-1709036-B1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1709036-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070926-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | GSK3B 173/4885P4HB 2397/4885HSD17B10 306/4885 |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | GSK3B 135/4885P4HB 2525/4885HSD17B10 329/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | GSK3B 456/4885P4HB 3891/4885HSD17B10 4656/4885 |
| US-10889576-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PKD2 | GSK3B 2598/4885P4HB 290/4885HSD17B10 264/4885 |
| US-10280160-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PKD2 | GSK3B 2598/4885P4HB 290/4885HSD17B10 264/4885 |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | GSK3B 2789/4885P4HB 1433/4885HSD17B10 409/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | GSK3B 456/4885P4HB 3891/4885HSD17B10 4656/4885 |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | GSK3B 3098/4885P4HB 363/4885HSD17B10 632/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | GSK3B 3098/4885P4HB 363/4885HSD17B10 632/4885 |
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | ADORA2B, ADRA2B, AGTR2 | GSK3B 4388/4885P4HB 439/4885HSD17B10 1066/4885 |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | GSK3B 173/4885P4HB 2397/4885HSD17B10 306/4885 |
| US-20190256505-A1 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PKD2 | GSK3B 2598/4885P4HB 290/4885HSD17B10 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.